

Oral Crizotinib induced severe esophageal ulcer with stenosis: a case report and literature review

Bingqiang Zhang¹, Song Wang¹, Binglan Zhang¹, Satish Chandra Yadav², and Xia Zhang¹

¹The First Affiliated Hospital of Chongqing Medical University

²International Organization for Migration Nepal

February 17, 2023

Abstract

Crizotinib is an oral [anaplastic lymphoma kinase](https://en.wikipedia.org/wiki/Anaplastic_lymphoma_kinase) and [c-ros oncogene 1](https://en.wikipedia.org/wiki/C-ros_oncogene_1) inhibitor, which is approved by the Food and Drug Administration for the treatment of metastatic non-small cell lung cancer (NSCLC). The 2011 Clinical trials demonstrated excellent treatment response, survival, and few side effects. We report a case of severe ulcerative oesophagitis with stenosis that was not reported in the 2011 Clinical trials and earlier studies.

Hosted file

pds-23-0064-File001.docx available at <https://authorea.com/users/587088/articles/624924-oral-crizotinib-induced-severe-esophageal-ulcer-with-stenosis-a-case-report-and-literature-review>